Article

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Molecular Cancer Therapeutics (Impact Factor: 6.11). 02/2009; 8(2):407-14. DOI: 10.1158/1535-7163.MCT-08-0854
Source: PubMed

ABSTRACT Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1%, P = 0.005; GBM22: 54.4%, P = 0.043). ABT-888 had no effect with radiotherapy alone but significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/temozolomide. With multicycle therapy, ABT-888 further extended the survival benefit of temozolomide in the inherently sensitive GBM12 and GBM22 xenograft lines. However, after in vivo selection for temozolomide resistance, the derivative GBM12TMZ and GBM22TMZ lines were no longer sensitized by ABT-888 in combination with temozolomide, and a similar lack of efficacy was observed in two other temozolomide-resistant tumor lines. Thus, the sensitizing effects of ABT-888 were limited to tumor lines that have not been previously exposed to temozolomide, and these results suggest that patients with newly diagnosed glioblastoma may be more likely to respond to combined temozolomide/poly(ADP-ribose) polymerase inhibitor therapy than patients with recurrent disease.

Download full-text

Full-text

Available from: Nicola J Curtin, Jul 07, 2015
0 Followers
 · 
99 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi). PARP is involved in single-strand DNA breaks, which in the presence of defective homologous recombination repair lead to double-strand DNA breaks, the most lethal form of DNA damage. These agents therefore may be the drugs of choice for BRCA mutant breast and ovarian cancers. PARPi result in synergistic antitumor effects when combined with cisplatin, temozolomide, topoisomerase inhibitors and ionizing radiation. The indications for PARPi lie beyond BRCA mutations and may include genomic and functional defects in DNA repair and damage response pathways. Several PARPi are in the clinical development phase at this time and, given the recent failure of a phase III clinical trial of iniparib in triple-negative breast cancer, the identification of structural and functional differences between these inhibitors becomes critical. Acquired resistance to PARPi is being noted and represents an important limitation in this field. A concise review of the literature in this field is presented.
    rapeutic Advances in Medical Oncology, The 11/2011; 3(6):257-67. DOI:10.1177/1758834011417039
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes a new TCP variation called Formosa that significantly improves TCP end-to-end performance in terms of high connection throughput and high degree of fairness in resource sharing among multiple competing connections in asymmetric networks. Existing TCP implementations are based on the ACK-clock, which clocks out a single data packet on receipt of an ACK. Formosa TCP pushes the frequency of ACKs per round trip time (RTT) to the lowest limit, using an ACK to cumulatively acknowledge a window's worth of data packets. The congestion window is updated to reflect the available bandwidth estimated on the forward channel, without the aid of the intermediate routers. As a result, the number of ACK packets is significantly reduced, while the principle of “conservation of packets” is still maintained. Based on “an ACK per window,” Formosa estimates forward delay and implements the additive increase and multiplicative decrease algorithm for better congestion avoidance. In addition, it employs the negative acknowledgement mechanism for better congestion control during loss recovery. As compared to existing implementations, TCP Formosa demonstrates the best performance in terms of high connection throughput, high degree of fairness among connections and robustness in the face of two-way transfers in asymmetric networks
    Communications, 2001. ICC 2001. IEEE International Conference on; 02/2001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There has been a recent upsurge in the development of small-molecule inhibitors specific to DNA repair proteins or proteins peripherally involved in base excision repair and the DNA damage response. These specific, nominally toxic inhibitors are able to potentiate the effect of existing cancer cell treatments in a wide array of cancers. One of the largest obstacles to overcome in the treatment of cancer is incomplete killing with initial cancer treatments, leading to resistant cancer. The progression of our understanding of cancer and normal cell responses to DNA damage has allowed us to develop biomarkers that we can use to help us predict responses of cancers, more specifically target cancer cells and overcome resistance. Initial successes using these small-molecule DNA repair inhibitors in target-validation experiments and in the early stages of clinical trials indicate an important role for these inhibitors, and allow for the possibility of a future in which cancers are potentially treated in a highly specific, individual manner.
    Future Oncology 07/2009; 5(5):713-26. DOI:10.2217/fon.09.31 · 2.61 Impact Factor